ABVC
ABVC BIOPHARMA, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.00
+1.51%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.98
From 52W high−66.56%
Volume42561.00
Market cap$26.69M
P/E (TTM)—
P/S (TTM)−33.5x
Div yield—
Key dataNov 4, 2026
Open
$0.98
From 52W high
−66.56%
Volume
42561.00
Market cap
$26.69M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.9x
P/E (TTM)
—
RSI (14)
47.7
MomentumView details →
1D Return
+1.51%
YTD Return
−53.42%
SummaryUpdated Jun 1, 2026
ABVC BioPharma, Inc. (NASDAQ:ABVC) is a clinical-stage biopharmaceutical company founded in 2004 and headquartered in Fremont, California. The company operates as a subsidiary of YuanGene Corporation and focuses on developing innovative drugs and medical devices to address unmet medical needs. ABVC has built a diverse pipeline of therapeutic candidates targeting various conditions including cancer, mental health disorders, and retinal diseases, with multiple compounds currently progressing through different phases of clinical trials.
Similar companies
Latest newsMore news →
ABVC BioPharma closed a private placement of original issue discount senior convertible promissory notes, generating approximately $3.39 million in gross proceeds before fees and expenses.2d agoABVC BioPharma entered into a private placement of senior convertible promissory notes with an aggregate principal amount of $4,106,060 and a purchase price of $3,387,500.2d agoABVC BioPharma entered into a settlement agreement with Lind under which it will pay $625,000 and Lind Notes will be cancelled upon receipt of payment.2d ago